MARKET

GENB

GENB

Generate Biomedicines
NASDAQ
11.22
-0.31
-2.69%
Opening 11:45 04/10 EDT
OPEN
11.69
PREV CLOSE
11.53
HIGH
11.73
LOW
11.11
VOLUME
86.16K
TURNOVER
--
52 WEEK HIGH
15.32
52 WEEK LOW
11.00
MARKET CAP
1.43B
P/E (TTM)
-5.7309
1D
5D
1M
3M
1Y
5Y
1D
Generate Biomedicines publishes corporate presentation on programmable biology drug design platform
Reuters · 2d ago
Largest IPOs of the last 90 days register mixed debut
Seeking Alpha · 4d ago
Weekly Report: what happened at GENB last week (0330-0403)?
Weekly Report · 4d ago
Weekly Report: what happened at GENB last week (0323-0327)?
Weekly Report · 03/30 10:48
UPDATE 2-Kailera Therapeutics files for US IPO
Reuters · 03/27 20:14
Friday's ETF Movers: SLVR, ARKG
NASDAQ · 03/27 18:18
BUZZ-Morgan Stanley bullish on Generate Biomedicines, cites strength of lead asthma drug
Reuters · 03/25 17:52
Generate Biomedicines: Differentiated AI-Driven Protein Platform with GB-0895 Asthma Lead and Emerging Oncology Upside Justifies Buy Rating
TipRanks · 03/25 14:45
More
About GENB
Generate Biomedicines, Inc. is a clinical-stage generative biology company focusing on the Artificial intelligence (AI) revolution in biotechnology and drug design and development. The Company is engaged in the field of generative biology using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its Generate Platform integrates generative and predictive models that learn design principles from proprietary data and graph neural networks, among other architectures. Its lead product candidate, GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma. Its other product candidates include GB-4362, a systemically administered monoclonal antibody designed to neutralize free monomethyl auristatin E (MMAE) as an adjunctive therapy to antibody-drug conjugate (ADC) molecules with an MMAE payload, as well as GB-5267, an armored, MUC16-directed CAR-T cell therapy candidate.

Webull offers Generate Biomedicines Inc stock information, including NASDAQ: GENB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GENB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GENB stock methods without spending real money on the virtual paper trading platform.